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Physiological studies involving the use of isotopic water required chemical restraint of free-
ranging walruses (Odobenus rosmarus) for several hours. In August 2000, six male walrus 
(total body mass: 1050–1550 kg) were immobilized in East Greenland by remote delivery of 
8.0–9.8 mg of etorphine and subsequently restrained for up to 6.75 h by administration of 
medetomidine. The effects of etorphine were reversed with 10–24 mg diprenorphine. After 
termination of the etorphine-induced apnoea, lasting an average of 15.8 min (SD = 9.7, 
range = 9.5–35.2 min, n = 6), the animals were initially given 10–20 mg medetomidine 
intramuscularly. The initial dose was further augmented by 5 mg at intervals of 5 min. In two 
cases, when medetomidine was administered through a catheter inserted in the extradural 
vein, the animal became instantly apnoeic and regained respiratory function only after 
intravenous injection of the prescribed dose of the antagonist atipamezole and of the 
respiratory stimulant doxapram. After an average of 3.5 hours of immobilisation, rectal 
temperature began to increase and it is conceivable that this is the factor that will ultimately 
limit the duration of immobilisation. The animals became conscious and fully mobile shortly 
after an intravenous injection of a dose of atipamezole approximately twice the mass of the 
total dose of medetomidine given during the procedure followed by 400 mg of doxapram. It 
is concluded that medetomidine appears to be a suitable drug for chemical restraint of 
walruses for time-consuming procedures following initial immobilisation by etorphine. With 
animals of total body mass around 1,000–1,500 kg, the drug should be given intramuscularly 
in 10–20 mg increments (total mass 10–60 mg) until the breathing rate falls to approximately 





A variety of drugs or drug combinations has to date been used to immobilize 
walruses (Odobenus rosmarus) in the field, including phencyclidine and 
acepromazine (DeMaster et al. 1981), tiletamine and zolazepam (Stirling and 
Sjare 1988; Hills 1992; Griffiths et al. 1993), etorphine (Hills 1992; Born and 
Knutsen 1992; Griffiths et al. 1993; Acquarone et al. 2014) and carfentanil 
(Hills 1992; Lanthier et al. 1999). None has proven ideal for prolonged 
immobilization. Only Lydersen et al. (1992) have tried a prolonged 
immobilisation of walrus. The animal was initially immobilized by 
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intramuscular (i.m.) administration of 5 mg (5.2 μg · kg-1) etorphine. The 
effect of the etorphine was reversed, as prescribed, by its antagonist 
diprenorphine. To keep control over the animal, a combined dose of 80 mg 
medetomidine and 1000 mg ketamine was then administered, before complete 
recovery, and provided restraint for further 5 h. (Lydersen et al. 1992). An 
investigation of body water dynamics and energy expenditure in walruses in 
Greenland using isotope-labelled water (Acquarone et al. 2006; Acquarone 
and Born 2007) created the need to regularly immobilize and restrain the 
subjects for longer than typical to allow the injected isotopes to mix with the 
body water pool. 
 
MATERIALS AND METHODS 
 
The fieldwork was conducted at a haulout at Lille Snenæs (Dove Bay, 
Greenland; 76°52.7´N, 19 37.9´W) during August 2000. The site is a small 
sandy tombolo with an axis of about 50 m joining a low rocky outcrop to the 
coast. Sea access is on both sides and walruses typically haul out on the south-
eastern side in groups of up to 16 adult and subadult males. Females or young 
were not detected during this study. Weather conditions were fine during the 
immobilizations: dry weather, +3 to +7˚C;;  wind  force  1 to 4 m sec-1; sunny 
or overcast. 
 
Six adult male walruses were used in this study. Total body mass (TBM) was 
measured for one animal (Walrus 2) or estimated from measurements of 
standard body length and axillary girth using the equations in Born et al. 
(2003) and ranged from 1,050 to 1,550 kg. All were immobilized by remote 
administration of a dart containing 8.0–9.8 mg etorphine  (“M99”,  9.8mg · ml-
1, Vericore Ltd., Dundee, Scotland) as described in Griffiths et al. (1993) and 
Acquarone et al. (2014). Etorphine was antagonized by hand delivered i.m. 
injections of 6–15 mg of diprenorphine   (“M5050”,   12mg · ml-1, Vericore 
Ltd., Dundee, Scotland) in the posterior dorsal region. Three of the animals 
were immobilized for the first time (animals 1-3: Table 1); one had been 
immobilized previously twice in 1989 and once in 1990 (animal 4: Table 1), 
and the last two (animals 5, 6: Table 1) had been immobilized previously three 
times and twice respectively during the same month. 
 
The etorphine/diprenorphine protocol used for immobilisation of all walruses 
is described in detail in Acquarone et al. (2014, this volume). In this report 
we only present information on a sub-set of six walruses that were treated 
with medetomidine after they had received etorphine and diprenorphine. In 
brief, the animals did not receive any premedication and were chosen for their 
calm behaviour and placement favourable to darting. Onset of tremors a few 
minutes after darting with etorphine indicated the end of the induction phase, 
the  time for  delivery of  diprenorphine  and the possibility to approach.  All 
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Table 1. Data on the use of etorphine/diprenorphine for the immobilisation of six walruses 
that were further kept restrained by use of medetomidine/atipamezole directly after regaining 




















1 5 2000-3 1,050 9.8 2.0 9.5 4.7 14.4 17.4 
2 9 2000-6 1,090 9.8 1.9 10.3 5.3 12.0 12.0 
3 15 2000-8 1,300 9.8 3.5 11.8 8.5 10.0 10.0 
4 18 1989-3 1,550 9.8 3.8 35.2 8.3 12.0 12.0 
5 19 2000-4 1,280 8.0 3.7 14.7 7.6 12.0 24.0 
6 22 2000-2 1,250 8.0 4.6 13.5 7.3 12.0 12.0 
(*) = Total Body Mass 
(**) = Minutes from darting with etorphine 
 
 
animals showed a variable apnoeic period starting at the end of the induction 
phase during which they were intubated to facilitate the resumption of 
breathing. Breathing in the period following the first administration of 
diprenorphine was forced: deeper and considerably faster than pre-
immobilisation. 
 
Some 30–40 min after the resumption of breathing, when the respiratory rate 
had fallen to around 8 min-1 and was not longer forced, six walruses started 
to emerge from immobilisation, as seen by beginning to open their eyes and 
move their head, which rendered venous access impossible. At this point they 
were given an intramuscular injection of 10–20 mg medetomidine  (“Domitor  
Forte”,  10mg · ml-1, Orion Pharma, Turku, Finland) (in the first animal only, 
a mixture of medetomidine and ketamine) every 5 min until they again were 
sufficiently sedated to allow the placement of a catheter (Becton-Dickinson 
Secalon-T, 2.0mm x 160mm, Medisinsk Utstyr AS, Oslo, Norway) into the 
extradural intravertebral sinus for blood sampling. In two cases, 
medetomidine was also given intravenously (i.v.). A 25 cm-long luer-lock 
extension set (Becton-Dickinson Connecta, Medisinsk Utstyr AS, Oslo, 
Norway) was attached to the indwelling catheter to facilitate blood sampling 
with minimum disturbance to the animal. The catheter and extension were 
flushed with heparinized saline following each blood sampling. For two 
walruses plasma was collected and sent to Orion Pharma, Turku, Finland, for 
medetomidine level determination. Body temperature was measured using an 
electronic thermometer (DM852, Ellab, Copenhagen, Denmark) with a probe 
inserted approximately 20 cm in the rectum. Heart rate was monitored with 
an electronic pulse meter (Exersentry, Respironics Instruments, Inc., 
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Monroeville, Pennsylvania 15146, U.S.A.) equipped with four sensors 
connected to 6 cm long needles inserted, as far as possible from each other, 
through  the  skin.  The  animals’  head  was  covered  with  a  towel  to  shade  the  
eyes from direct sun light and prevent visual stimuli during handling. 
 
If an animal showed signs of arousal (head lift, body movement), it was given 
additional medetomidine i.m. or i.v. At the conclusion of the sampling period 
the walrus was given the D2 antagonist atipamezole  (“Antisedan”,  5 mg · ml-
1, Orion Pharma, Turku, Finland) at a rate of approximately twice the mass of 
the total medetomidine administered. The dose was given either half 
intravenously (i.v.) and half i.m., or wholly i.m. If an animal went into apnoea 
after the administration of medetomidine, it was given i.v. atipamezole at a 
rate of twice the mass of medetomidine injected, followed by 400mg of the 




Six walruses received i.m. medetomidine following reversal of the etorphine 
with diprenorphine (Table 1). In the search for the most appropriate prolonged 
immobilisation method two of these six animals were at some stage given 
medetomidine i.v., but in both cases this led to immediate apnoea that could 
only be reversed by the antagonist atipamezole (discussed below). The first 
of the six animals received a combination of ketamine and medetomidine (see 
below, Animal 1). This animal also stopped breathing, and breathing resumed 
only after i.v. injection of atipamezole and doxapram. All subsequent animals 
received only medetomidine i.m.  
 
Walrus 1 (estimated TBM: 1,050 kg) received 9.8 mg etorphine that was 
reversed with 14.4 mg diprenorphine (Table 1). Drug-induced apnoea lasted 
a total of 9.5 min and the animal was breathing in a controlled and regular 
manner at 17 min post darting. (All records of time are time in relation to 
initial impact of the dart containing etorphine unless otherwise stated.) This 
animal was given 24 mg medetomidine and 260 mg ketamine i.m. at 1.28 h 
post-darting and at 1.33 h ceased breathing. At 1.42 h it was given 70 mg 
atipamezole with 400 mg doxapram i.v. and resumed breathing 2 min later. It 
remained totally immobile for the next 25 min, when it stopped breathing 
again. This time, however, it could be aroused enough for head-lifting and 
breathing by physical stimulation of the muzzle, after which it would again 
lower its head and become apnoeic. It was aroused in this way every two 
minutes to breathe until 2.68 h, when it was given a further 50 mg atipamezole 
i.m. At 2.72 h it resumed spontaneous breathing, but otherwise lay immobile. 
At 2.97 h a blood sampling was attempted, but this aroused the animal totally 
and stimulated it to enter the sea. It was recaptured five days later and from 
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observations made before the new immobilisation it behaved normally. Six 
days later it was observed once again by the haulout. 
 
Walrus 2 (measured TBM 1,090 kg) was immobilized with 9.8 mg etorphine 
that was reversed with 12.0 mg diprenorphine. Drug-induced apnoea lasted 
10.3 min and the breath became regular at 14 min post darting (Table 1). This 
walrus received 10 mg medetomidine i.m. at 35 min with no observable effect 
on breathing, and a further 5 mg i.m. at 45 min, which resulted in the breathing 
becoming shallower, interspersed with occasional deep breaths. 
Immobilisation was sufficient to allow the walrus to be rolled onto a scale and 
weighed. By 2.37 h it had begun to move its flippers and body and was given 
5 mg medetomidine i.v. It stopped breathing almost immediately, however, 
and at 2.43 h was given 40 mg atipamezole and 500 mg doxapram i.v. At 
2.50 h it arose, with apparent full reversal of all immobilization, entered the 
sea and strongly swam away. This animal was recaptured both 3 and 13 days 
later and in both occasions it behaved normally. 
 
Walrus 3 (estimated TBM 1,300 kg) received 9.8 mg etorphine and 10.0 mg 
diprenorphine. Duration of drug-induced apnoea was 11.8 min and the animal 
was breathing regularly at 21 min post darting (Table 1). Walrus 3 was given 
10 mg medetomidine at 39 min (with no effect) and a further 5 mg at 44 min, 
after which the breathing rate fell from 12 to around 4 min-1. The walrus 
remained immobile for the next 2.5 h, after which it began to rock its torso 
and move its head with breathing. At 3.53 h and again at 3.62 h it received 
5 mg of medetomidine i.m. after which it again lay still with regular breathing. 
At 6.67 h it was given 30 mg atipamezole i.m., and four minutes later it sat 
up and went into the sea, apparently fully awake. Walrus 3 was recaptured 
three days later, and also three times the following year. On every occasion it 
behaved normally. 
 
Walrus 4 (estimated TBM 1,550 kg) received 9.8 mg etorphine and 12.0 mg 
diprenorphine. Drug-induced apnoea lasted 35.2 min and regular breathing 
was resumed 44 min post darting (Table 1). This individual received 12 mg 
medetomidine i.m. at 1.00 h and a further 3 mg i.m. at 1.08 hr. Thereafter it 
lay immobile with regular breathing until about 1.50 h, when it began to move 
its torso and rear flippers intermittently. It did not react, however, to insertion 
of a needle into the extradural space for blood sampling and was not given 
additional medetomidine. At 2.88 h it sat up abruptly and entered the sea, 
apparently totally recovered and without the use of atipamezole. This animal 
had been already immobilized by etorphine darting both in 1989 and 1990 
and was also immobilized twice the following year (2001). 
 
Walrus 5 (estimated TBM 1,280 kg) received 8.0 mg etorphine and 24.0 mg 
diprenorphine. Drug-induced apnoea lasted 14.7 min and at 18.5 min post 
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darting the walrus had resumed regular breathing (Table 1). Walrus 5 received 
20 mg medetomidine i.m. at 30 min. At 45 min it showed some body-rocking, 
and reacted to the insertion of a rectal thermometer and to tapping on a tusk, 
and was given a further 10 mg medetomidine i.m. at 1.06 h. At 1.83 h it was 
given 5 mg medetomidine i.v. and stopped breathing almost immediately. 
Several minutes later breathing had not recommenced and there was no 
response to the i.v. injection of 500 mg doxapram. At 1.90 h it was given 
25 mg atipamezole i.v. Shortly after it again began to breathe at a rate of about 
1 min-1, but continued to lie immobile without response to tactile stimulation. 
After 15–20 min this respiratory pattern became Cheyne-Stokes-like, with 3–
5 deep breaths every couple of minutes. Approaching 5 h immobility, the 
breathing pattern reverted to a regular one, about 1 min-1. At 5.48 h the walrus 
was given 50 mg atipamezole, half i.m. and half i.v., and at 5.53 h it sat up 
and entered the sea of its own accord, apparently normal. Even though this 
animal was not seen at haulout later this season, its movements have been 
followed by satellite tacking for more than 100 days after this immobilization 
without any sign of abnormal behaviour.  
 
Walrus 6 (estimated TBM 1,250 kg) received 8.0 mg etorphine and 12.0 mg 
diprenorphine. Drug induced apnoea lasted 13.5 min and the animal was 
breathing regularly at 21 min post darting. This animal was given 20 mg 
medetomidine i.m. at 40 min, 45 min and 55 min, a total of 60 mg. After the 
third dose its breathing rate fell from 6 min-1 to 1–2 min-1. As with walrus 5, 
its breathing changed to a Cheyne-Stokes-like pattern, with several good 
breaths every 1.5–2.5 min (Fig. 1). The heart rate altered cyclically with the 
breathing, from typically around 30–45 min-1 between breaths to 65–70 min-
1 just prior to and during breathing. At 3.42 h the animal showed signs of 
arousal, with some body-rocking and flipper movement, and shorter intervals 
between breaths. At 4.23 h and 4.32 h it lifted its head and moved a little 
forwards, but otherwise continued to lie quietly. At 4.78 h it was given 100 mg 
atipamezole i.m., and at 4.88 h it sat up and entered the sea without apparent 
sedation. Walrus 6 was a frequent occupant of the haulout the following year 
when it was immobilized further 3 times and on every occasion it behaved 
normally. 
 
The duration of immobilisations ranged from 2.36 h to 6.75 h. In all cases 
except one in which the animal suddenly arose and entered the sea without 
receiving the antagonist, arousal was induced by injection of atipamezole. 
 
Plasma medetomidine concentration was measured by the producers of the 
drug (Orion Pharma, Turku, Finland) in animals 5 and 6. In both animals, 
concentration was initially low, and then increased to variable levels during 
the following hours (Table 2). There was no apparent consistent trend in 
plasma medetomidine concentration with time, but it is worth noting that the 
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Fig. 1. Breathing rate of an adult male walrus (no. 6) during 
immobilisation with medetomidine following an initial immobilisation 
with etorphine/diprenorphine. Time (min) is given relative to darting with 
etorphine (i.e. the first dose of medetomidine was injected 40 min after 
darting). The breathing rate was greatly reduced after the third 
medetomidine injection, and after a further 0.5h was transformed into a 
more intermittent pattern with several breaths at intervals of several 
minutes. 
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concentration did not decline with time and was still high at the time of 
reversal of the drug.  
 
Table 2. Medetomidine concentrations in blood plasma of two 
adult male walrus in relation to time during immobilisation 




Plasma Medetomidine concentration  
(ng ml-1) 




1.5 No sampling 2.81 
2.0 No sampling 19.7 
2.5 9.24 18.6 
3.0 9.82 13.7 
3.5 5.11 9.42 
4.0 12.1 9.66 
4.5 11.5 15.0 
5.0 6.33  
5.5 5.54  
 
 
Rectal temperature was measured in animals 3, 4, 5 and 6 (Fig. 2). Rectal 
temperature shortly after initial immobilisation with etorphine ranged 35.8 to 
37.0 °C, and remained below 38.0 °C for some 2–3 hr. Thereafter there was 
a tendency for the rectal temperature to increase slowly to around 38 °C, 
although it never approached 42 °C at which protein denaturation and thus 




The choice of employing medetomidine for restraint after immobilisation by 
etorphine was taken after considerations on employing medetomidine as the 
immobilizing agent instead of etorphine. However, initial trials in 1999 with 
medetomidine and Telazol® in two animals proved fatal in both cases 
(Griffiths unpublished) and indicated that this combination is not suitable for 
immobilisation without extensive testing. Considering the small walrus 
populations on both Greenland and Spitsbergen, it was decided not to risk 
more casualties and to revert to the familiar immobilisation drug, etorphine, 
as the first drug. 
 
Griffiths et al. (2014) Online Early Version 
NAMMCO Scientific Publications, Volume 9 
Fig. 2. Rectal temperature in relation to time (min after darting 




Medetomidine appeared to be suitable as an agent for immobilisation 
maintenance, following etorphine, when prolonged immobilisation of 
walruses is necessary. When the animal appears to have recovered from the 
initial etorphine drugging and is breathing regularly and unlaboured at a rate 
of 6–8 min-1 (which for the animals in this study was at about 35–40 min from 
darting) it may be given medetomidine, using respiratory rate and pattern as 
an indicator of depth of anaesthesia. Medetomidine is to be given i.m. at 5–
20 mg increments every five minutes until the respiratory rate falls to 
approximately 1 min-1. The amount of medetomidine required to achieve this 
effect ranged in this trial between 15 and 60 mg. In the two animals 
immobilized the longest (5 and 6), the breathing pattern subsequently 
changed to an intermittent type, with bursts of several breaths interspersed 
with periods of apnoea up to 4 min in duration.  
 
The variation in recovery time after etorphine immobilisation (Table 1) may 
indicate residual central nervous system depression, which in turn may 
influence the amount of medetomidine needed to re-immobilize the animals. 
The large variation in the dose of medetomidine needed to immobilize the 
walruses (15–60 mg or 9.7–22.9 µg · kg-1) is therefore probably related to the 
effects of the initial etorphine drugging. However, there is potential 
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is unknown, making calculation of dosage of any agent by metabolic weight 
difficult. 
 
There was considerable variation in the duration of medetomidine 
immobilisation before additional medetomidine was needed (2.0–3.5 hrs). 
Repeated dosage should be administered i.m. and in small increments, with 
respiratory rate again being the key indicator of level of sedation. Signs of 
arousal from sedation included rocking of the torso in association with 
breathing, movement of the rear flippers, head movement and increased 
respiratory rate to at least one breath per minute. These signs are similar to 
those observed after reversal of etorphine with diprenorphine in which some 
walruses quickly become mobile and enter the sea of their own accord, 
reacting aggressively to human proximity. Others will recommence breathing 
and show head-lift, but appear unwilling to ambulate, do not respond to 
physical contact other than with head-lift, and may remain in the same 
position for over a day. 
 
In all cases intravenous administration of medetomidine, even a dose as small 
as 5 mg, led to immediate cessation of breathing as previously reported 
(Lydersen et al. 1992). Only the use of the antagonist atipamezole could start 
breathing again. We conclude after several attempts to administer 
medetomidine i.v. that this route is absolutely contraindicated in the walrus, 
at least following the use of etorphine.  
 
In all cases, rectal temperature remained nearly unaltered for a couple of hours 
of immobilisation (Fig. 2). No attempts were made to cool the animals or 
otherwise regulate body temperature during immobilization. There was a 
trend for temperature to increase with prolonged immobilisation to around 38 
°C by the time the immobilisation was reversed. Whether rectal temperature 
would have continued to increase or have levelled off is unknown. The fact 
that the rectal temperature increased in the three animals monitored for more 
than two hours indicates that medetomidine may impair thermoregulation in 
walrus.  
 
All these animals apparently did survive and were observed directly or 
followed through satellite tracking several weeks and even a year after 
immobilisation. This procedure did not seem to have a significant impact on 
their survival. Despite the survival of the immobilized animals in this case 
study, prolonged anaesthesia had profound effects on the ventilation of these 
animals and therefore does represent a risk. None of the data presented here 
enable us to evaluate the effect of prolonged immobilisation on the O2 and 
CO2 levels in these animals. Blood gas analysis or indirect method (ex: 
capnometry) could provide useful information but was not possible in this 
situation. Supplemental oxygen was not used to improve the oxygenation, 
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also due to logistical restrictions, but its importance in the treatment of 
animals with marked depressed ventilation is acknowledged and we 
recommend its use. 
 
In summary, medetomidine appears to be a suitable drug for immobilisation 
of walruses for time-consuming procedures following initial capture with 
etorphine and reversal with diprenorphine. With animals weighing 1,000–
1,500 kg, the drug should be given intramuscularly in 5–20 mg increments 
(total mass 10–60 mg) until the breathing rate falls to approximately 1 min-1. 
At this level, breathing is maintained and animals do not respond to touch or 
injection. A rectal thermometer should be used, since after several hours of 
immobilisation rectal temperature begins to increase and it is conceivable that 
this is the factor that will ultimately limit the duration of immobilisation 
possible. Finally the evaluation of the severity of hypoxia and hypercapnia is 
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